Ernexa Therapeutics Inc.
General ticker "ERNA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $11.2M (TTM average)
Ernexa Therapeutics Inc. does not follow the US Stock Market performance with the rate: -29.2%.
Estimated limits based on current volatility of 5.4%: low 6.33$, high 7.05$
Factors to consider:
- Total employees count: 9 as of 2022
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Insufficient capital, Regulatory and compliance, Clinical trial failure, IP protection failure, Manufacturing risks
- Current price 40.8% below estimated low
- Earnings for 15 months up through Q1 (+1 year) exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [32.82$, 183.16$]
- 2025-12-31 to 2026-12-31 estimated range: [10.88$, 59.87$]
Financial Metrics affecting the ERNA estimates:
- Negative: with PPE of -1.2 at the end of fiscal year the price was very high
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Negative: negative Net income
- Negative: negative Industry operating cash flow (median)
- Negative: negative Industry operating income (median)
- Negative: Inventory ratio change, % of 73.64 > 0.80
- Negative: Interest expense per share per price, % of 6.02 > 3.34
Short-term ERNA quotes
Long-term ERNA plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.07MM | $0.58MM |
| Operating Expenses | $33.22MM | $21.20MM | $16.26MM |
| Operating Income | $-33.22MM | $-21.14MM | $-15.67MM |
| Non-Operating Income | $8.68MM | $-0.54MM | $-28.84MM |
| Interest Expense | $0.03MM | $0.61MM | $6.75MM |
| R&D Expense | $10.39MM | $5.92MM | $4.60MM |
| Income(Loss) | $-24.53MM | $-21.67MM | $-44.51MM |
| Taxes | $0.04MM | $-0.00MM | $0.03MM |
| Net Income(Loss)* | $-24.58MM | $-21.73MM | $-44.54MM |
| Stockholders Equity | $12.11MM | $2.23MM | $1.70MM |
| Assets | $22.28MM | $49.13MM | $5.27MM |
| Operating Cash Flow | $-20.98MM | $-20.41MM | $-15.84MM |
| Capital expenditure | $0.30MM | $0.02MM | $0.37MM |
| Investing Cash Flow | $-0.05MM | $-0.02MM | $-0.36MM |
| Financing Cash Flow | $19.58MM | $16.56MM | $6.26MM |
| Earnings Per Share** | $-201.40 | $-102.22 | $-39.21 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.